c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients

Sabino De Placido, Chiara Carlomagno, Michelino De Laurentiis, Angelo Raffaele Bianco

Research output: Contribution to journalArticlepeer-review


c-erbB2 is a proto-oncogene that encodes the trans-membrane protein p185. This protein shares considerable sequence and structure homology with members of the epidermal growth factor receptor family and it is believed to cooperate with these receptors in the signal transduction process in order to control cell proliferation. Overexpression of c-erbB2, with or without gene amplification, is frequently found in breast cancer, and a body of evidence suggests it is implicated in the development of resistance to the antiestrogen tamoxifen. Scientific evidence strongly supports a correlation between c-erbB2 overexpression and lack of efficacy of tamoxifen in both advanced and adjuvant settings. However, given the important therapeutic repercussion of this topic, further studies are required before c-erbB2 evaluation can be routinely used to select patients who are likely to benefit from tamoxifen administration.

Original languageEnglish
Pages (from-to)55-64
Number of pages10
JournalBreast Cancer Research and Treatment
Issue number1-3
Publication statusPublished - 1998


  • c-erbB2
  • Predictive factors
  • Tamoxifen resistance
  • Treatment response

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients'. Together they form a unique fingerprint.

Cite this